|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| Endo Pharmaceuticals Holdings Inc. - SWOT Analysis |
|
|
|
|
€ 100,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Mars 2008 |
Taille du document : |
28 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
ePharmacies: Strategic Implications for the Healthcare Industry
230 pages | Mars 2000 |
Increasingly, the pharmaceutical sector is being influenced by the Internet.Are you in a position to:- Predict future shifts in drug prescribing and purchasing behavior?- Anticipate consolidation in b |
955,00 €
|
| |
| |
The Global Parallel Trade Outlook 2001 - 2006: A Country-by-Country Analysis
188 pages | Septembre 2001 |
Global Parallel Trade Outlook 2001: A country-by-country analysis, a new report by Reuters Business Insight, provides a detailed update on the status of parallel trade in the global marketplace.
1 200,00 €
|
|
| |
| |
Pharmaceutical Pricing Strategies 2000: Entering the new millennium
240 pages | Juin 2000 |
The favorable climate of the pharmaceutical sector has changed radically over the past ten years.
Where once a company's freedom over pricing decisions was almost limitless, external pressure |
955,00 €
|
| |
| |
Pharmaceutical Packaging: UK
90 pages | Avril 2000 |
· Analyse the changes in demand for pharmaceutical packaging in the UK, over the next 5 years
· Understand the main factors affecting demand
· Examine the struct |
1 249,31 €
|
| |
| |
Healthcare In Wales
50 pages | Mai 2000 |
The Welsh Presentation Includes:- The Structure Of The NHS In Wales- Revenue Expenditure On Health Services In Wales- Number Of Hospital Units - Number Of Available Inpatient Beds- Number Of Occupied |
327,00 €
|
| |
| |
The Evolution of DTC marketing across key pharmaceutical markets
152 pages | Mars 2000 |
Pharmaceutical companies mainly market their products through contact between their sales force and heathcare providers.
However, due to the nature of its products, the pharmaceutical industry |
955,00 €
|
| |
| |
Strategic Intelligence: The Top 12 Pharmaceutical Companies
158 pages | Novembre 2001 |
The pressure on the pharmaceutical company R&D has never been greater.
It is estimated that $100 billion worth of products will face patent expiry by 2005.
Of this, $37 billion represe |
1 021,89 €
|
| |
| |
The Pharmaceutical industry in the 21st Century
150 pages | Octobre 1998 |
Does the 21st century herald the beginning of a genomics revolution? Which disease areas will provide the greatest growth potential and why? Which technologies have the greatest potential to max |
795,00 €
|
| |
| |
The Drug Delivery Outlook to 2005
150 pages | Février 1999 |
Strategic overview : defines and values the market covered in the report, provides a macro analysis of the reasons why the drug delivery sector is growing at current rates and predicts how the c |
795,00 €
|
| |
| |
Regulatory Affairs: Paths to Approval
113 pages | Février 1999 |
Area Specific Chapters : The regulatory systems governing clinical trials and drug approvals are examined for the US, Europe, and Australia, Canada and Japan, including analysis of the implicatio |
795,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Endo Pharmaceuticals Holdings Inc. - SWOT Analysis |
|
|
Datamonitor's Endo Pharmaceuticals Holdings Inc. - SWOT Analysis Company Profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.
Endo Pharmaceuticals (Endo) engages in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used for the treatment and management of pain. The company primarily operates in the US. Endo is headquartered in Chadds Ford, Pennsylvania and employs about 1,000 people. The company recorded revenues of $1,085.6* million during the fiscal year ended December 2007, an increase of 19.3% over 2006. The operating profit of the company was $317.2 million during fiscal year 2007, an increase of 50.7% over 2006. The net profit was $227.4 million in fiscal year 2007, an increase of 65% over 2006. *Financials are unaudited http://phx.corporate-ir.net/phoenix.zhtml?c=123046&p=irol-newsArticle&ID=1111324&highlight=
Scope of the Report
- Provides all the crucial company information required for business and competitor intelligence needs
- Contains a study of the major internal and external factors affecting the company in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams
- Data is supplemented with details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement
Reasons to Purchase
- Support sales activities by understanding your customers’ businesses better
- Qualify prospective partners and suppliers
- Keep fully up to date on your competitors’ business structure, strategy and prospects
- Obtain the most up to date company information available
|
|
Table of Contents:
This product typically includes the following sections:
Key Facts
Company Overview
Business Description
Company History
Key Employees
Key Employee Biographies
Company View
SWOT analysis
Products & Services Listing
Products & Services Analysis
|
|
|
PPLSEN
|
|
|
|
|
